PubMed · 2005 · 119 citations · 111 references
MedicinePediatricsPsychiatryChild PsychiatryPediatric Mental HealthPsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyChild PsychopharmacologyPediatric Clinical TrialsPsychopharmacology In ChildrenAntipsychotic Medication UseAntipsychotic SafetyAtypical Antipsychotic TreatmentDisruptive Behavior Disorder TreatmentPediatric Antipsychotic UsePervasive Developmental DisorderTic Disorders In AdolescentsTic Disorders In Children
The comparable efficacy and improved safety of the atypical antipsychotics compared with the traditional antipsychotic agents in the treatment of schizophrenia and other disorders in adults have prompted the use of these agents in children and adolescents. The atypical antipsychotics are increasingly being used in children and adolescents with a variety of different psychiatric diagnoses, including schizophrenia, bipolar disorder, autism/pervasive developmental disorders, conduct disorder, depression, anxiety disorders, tic disorders, delirium, and eating disorders. Unfortunately, clinical use of these agents in pediatric patients has far exceeded the limited evidence from randomized controlled trials. This article reviews the available evidence from the published literature on the use of the atypical antipsychotics in children and adolescents with schizophrenia, bipolar disorder, and maladaptive aggression associated with autism/pervasive developmental disorders and conduct disorder/disruptive behavior disorders.
111
Risperidone in Children with Autism and Serious Behavioral Problems
James T. McCracken, James J. McGough, Bhavik Shah et al. · New England Journal of Medicine · 2002 · 1.6K citations · Full text